Literature DB >> 21781921

Inhibitory metabolite complex formation of methylenedioxymethamphetamine with rat and human cytochrome P450. Particular involvement of CYP 2D.

M Delaforge1, M Jaouen, G Bouille.   

Abstract

Methylenedioxymethamphetamine (MDMA or ecstasy) is a common recreational drug used at rave parties. Unfortunately, MDMA may have neurological effects and in some cases causes hepatotoxicity. MDMA binds to cytochrome P450 in rat and human hepatic microsomal preparations. Upon metabolic transformation of either the methylenedioxy or the methylamino function, it forms an inhibitory P450-metabolite complex. This inhibitory complex is formed predominantly with the P450 2D isozymes. This complex formation may account for the clinical toxicity observed upon ingestion of MDMA, particularly with other compounds normally metabolized by P450 2D6.

Entities:  

Year:  1999        PMID: 21781921     DOI: 10.1016/s1382-6689(99)00007-1

Source DB:  PubMed          Journal:  Environ Toxicol Pharmacol        ISSN: 1382-6689            Impact factor:   4.860


  12 in total

1.  In vitro metabolism of 3,4-methylenedioxymethamphetamine in human hepatocytes.

Authors:  Corinne Ramaley; Susan C Leonard; Jeffrey D Miller; Denita Takesha-Mashia Wilson; Sai Y Chang; Qingyu Chen; Feng Li; Chengan Du
Journal:  J Anal Toxicol       Date:  2014-03-28       Impact factor: 3.367

Review 2.  Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs.

Authors:  Michael H Baumann; Mohammad O Bukhari; Kurt R Lehner; Sebastien Anizan; Kenner C Rice; Marta Concheiro; Marilyn A Huestis
Journal:  Curr Top Behav Neurosci       Date:  2017

Review 3.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

4.  Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.

Authors:  Samanta Yubero-Lahoz; Ricardo Pardo; Magí Farré; Brian O'Mahony; Marta Torrens; Cristina Mustata; Clara Pérez-Mañá; Marcel Lí Carbó; Rafael de la Torre
Journal:  Clin Pharmacokinet       Date:  2011-05       Impact factor: 6.447

5.  Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.

Authors:  M Farré; R de la Torre; B O Mathúna; P N Roset; A M Peiró; M Torrens; J Ortuño; M Pujadas; J Camí
Journal:  Psychopharmacology (Berl)       Date:  2004-04-08       Impact factor: 4.530

Review 6.  Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.

Authors:  João Paulo Capela; Helena Carmo; Fernando Remião; Maria Lourdes Bastos; Andreas Meisel; Félix Carvalho
Journal:  Mol Neurobiol       Date:  2009-04-17       Impact factor: 5.590

Review 7.  Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.

Authors:  Rafael de la Torre; Magí Farré; Mónica Navarro; Roberta Pacifici; Piergiorgio Zuccaro; Simona Pichini
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat.

Authors:  Michael H Baumann; Dorota Zolkowska; Insook Kim; Karl B Scheidweiler; Richard B Rothman; Marilyn A Huestis
Journal:  Drug Metab Dispos       Date:  2009-08-13       Impact factor: 3.922

9.  Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat.

Authors:  Marta Concheiro; Michael H Baumann; Karl B Scheidweiler; Richard B Rothman; Gina F Marrone; Marilyn A Huestis
Journal:  Drug Metab Dispos       Date:  2013-10-18       Impact factor: 3.922

10.  MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?

Authors:  Rafael de la Torre; Samanta Yubero-Lahoz; Ricardo Pardo-Lozano; Magí Farré
Journal:  Front Genet       Date:  2012-11-12       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.